PURPOSE OF REVIEW: Progress in stem cell research for blinding diseases over the past decade is now being applied to patients with retinal degenerative diseases and soon perhaps, glaucoma. However, the field still has much to learn about the conversion of stem cells into various retinal cell types, and the potential delivery methods that will be required to optimize the clinical efficacy of stem cells delivered into the eye. RECENT FINDINGS: Recent groundbreaking human clinical trials have demonstrated both the opportunities and current limitations of stem cell transplantation for retinal diseases. New progress in developing in vitro retinal organoids, coupled with the maturation of bio-printing technology, and non-invasive high-resolution imaging have created new possibilities for repairing and regenerating the diseased retina and rigorously validating its clinical impact in vivo. SUMMARY: While promising progress is being made, meticulous clinical trials with cells derived using good manufacturing practice, novel surgical methods, and improved methods to derive all of the neuronal cell types present in the retina will be indispensable for developing stem cell transplantation as a paradigm shift for the treatment of blinding diseases.
PURPOSE OF REVIEW: Progress in stem cell research for blinding diseases over the past decade is now being applied to patients with retinal degenerative diseases and soon perhaps, glaucoma. However, the field still has much to learn about the conversion of stem cells into various retinal cell types, and the potential delivery methods that will be required to optimize the clinical efficacy of stem cells delivered into the eye. RECENT FINDINGS: Recent groundbreaking human clinical trials have demonstrated both the opportunities and current limitations of stem cell transplantation for retinal diseases. New progress in developing in vitro retinal organoids, coupled with the maturation of bio-printing technology, and non-invasive high-resolution imaging have created new possibilities for repairing and regenerating the diseased retina and rigorously validating its clinical impact in vivo. SUMMARY: While promising progress is being made, meticulous clinical trials with cells derived using good manufacturing practice, novel surgical methods, and improved methods to derive all of the neuronal cell types present in the retina will be indispensable for developing stem cell transplantation as a paradigm shift for the treatment of blinding diseases.
Authors: M Haruta; M Kosaka; Y Kanegae; I Saito; T Inoue; R Kageyama; A Nishida; Y Honda; M Takahashi Journal: Nat Neurosci Date: 2001-12 Impact factor: 24.884
Authors: Jason S Meyer; Sara E Howden; Kyle A Wallace; Amelia D Verhoeven; Lynda S Wright; Elizabeth E Capowski; Isabel Pinilla; Jessica M Martin; Shulan Tian; Ron Stewart; Bikash Pattnaik; James A Thomson; David M Gamm Journal: Stem Cells Date: 2011-08 Impact factor: 6.277
Authors: David E Buchholz; Sherry T Hikita; Teisha J Rowland; Amy M Friedrich; Cassidy R Hinman; Lincoln V Johnson; Dennis O Clegg Journal: Stem Cells Date: 2009-10 Impact factor: 6.277
Authors: David Rodriguez-Crespo; Salvatore Di Lauro; Amar K Singh; Maria T Garcia-Gutierrez; Manuel Garrosa; J Carlos Pastor; Ivan Fernandez-Bueno; Girish K Srivastava Journal: Cell Tissue Res Date: 2014-09-12 Impact factor: 5.249
Authors: Athurva Gore; Zhe Li; Ho-Lim Fung; Jessica E Young; Suneet Agarwal; Jessica Antosiewicz-Bourget; Isabel Canto; Alessandra Giorgetti; Mason A Israel; Evangelos Kiskinis; Je-Hyuk Lee; Yuin-Han Loh; Philip D Manos; Nuria Montserrat; Athanasia D Panopoulos; Sergio Ruiz; Melissa L Wilbert; Junying Yu; Ewen F Kirkness; Juan Carlos Izpisua Belmonte; Derrick J Rossi; James A Thomson; Kevin Eggan; George Q Daley; Lawrence S B Goldstein; Kun Zhang Journal: Nature Date: 2011-03-03 Impact factor: 49.962
Authors: Jing Cao; Rong Yang; Taylor E Smith; Stephanie Evans; Gary W McCollum; Steven C Pomerantz; Theodore Petley; Ian R Harris; John S Penn Journal: Mol Ther Methods Clin Dev Date: 2019-05-22 Impact factor: 6.698
Authors: Nahla Jemni-Damer; Atocha Guedan-Duran; María Fuentes-Andion; Nora Serrano-Bengoechea; Nuria Alfageme-Lopez; Félix Armada-Maresca; Gustavo V Guinea; José Perez-Rigueiro; Francisco Rojo; Daniel Gonzalez-Nieto; David L Kaplan; Fivos Panetsos Journal: Front Bioeng Biotechnol Date: 2020-12-10
Authors: Ricardo Usategui-Martín; Kevin Puertas-Neyra; María-Teresa García-Gutiérrez; Manuel Fuentes; José Carlos Pastor; Ivan Fernandez-Bueno Journal: Mol Ther Methods Clin Dev Date: 2020-05-13 Impact factor: 6.698